TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 176 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $22,151,773 | +26.2% | 984,961 | +18.0% | 0.15% | +84.1% |
| Q4 2022 | $17,559,229 | -14.6% | 834,961 | 0.0% | 0.08% | -32.2% |
| Q3 2022 | $20,573,000 | +1.7% | 834,961 | 0.0% | 0.12% | -61.2% |
| Q2 2022 | $20,231,000 | -9.6% | 834,961 | -3.9% | 0.31% | +13.9% |
| Q1 2022 | $22,388,000 | -20.6% | 868,778 | -4.4% | 0.27% | -3.9% |
| Q4 2021 | $28,214,000 | +53.3% | 908,951 | +19.8% | 0.28% | +265.4% |
| Q3 2021 | $18,404,000 | +122.4% | 758,951 | +33.8% | 0.08% | +69.6% |
| Q2 2021 | $8,276,000 | +26.0% | 567,183 | +115.6% | 0.05% | +27.8% |
| Q1 2021 | $6,568,000 | – | 263,013 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |